论文部分内容阅读
目的观察单独应用瑞格列奈(诺和龙)、瑞格列奈(诺和龙)联合二甲双胍(格华止)及瑞格列奈(诺和龙)联合精蛋白生物合成人胰岛素中效注射液(诺和灵N)治疗2型糖尿病患者使其空腹血糖达标的方法探讨。方法选取门诊和住院的2型糖尿痛患者102例,随机分为A组单独应用诺和龙组34例、B组诺和龙联合格华止组38例、C组诺和龙联合诺和灵N组30例。三组基础治疗相同,疗程均为12周。分别测定治疗前后空腹血糖,馒头餐后2小时血糖,及糖化血糖蛋白。结果三组患者治疗前后血糖及糖化血红蛋白比较有显著改善,其中C组血糖及糖化血红蛋白达标最佳。结论三组临床治疗方法均可以明显的控制2型糖尿病患者的血糖及糖化血红蛋白,使其达标更加的应是C组诺和龙联合诺和灵N组。
Objective To observe the effects of repaglinide (Novolin), repaglinide (Novolin) combined with metformin (metformin) and repaglinide Method for the Treatment of Type 2 Diabetes Patients with Norfloxacin N to Achieve Fasting Blood Glucose. Methods A total of 102 outpatients and hospitalized type 2 diabetic patients were randomly divided into group A (n = 34), group A (n = 34), group B N group of 30 cases. The same three groups of basic treatment, treatment for 12 weeks. The levels of fasting blood glucose, postprandial 2-hour postprandial blood glucose and glycosylated glycoproteins were determined before and after treatment. Results Three groups of patients before and after treatment of blood glucose and glycosylated hemoglobin were significantly improved, of which C group of blood glucose and glycosylated hemoglobin achieve the best. Conclusion All the three groups of clinical treatment methods can obviously control the blood sugar and HbA1c of type 2 diabetic patients, so that the standard of them should be more C group of Novolin and Novolin N group.